Louis G. Lange - 07 Jan 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Director
Issuer ticker: NAMS
Reported as of: 07 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 19:33:10 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange

Key filing fact

Louis G. Lange filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 09 Jan 2026.

Key facts

This page summarizes Louis G. Lange's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2026, 19:33.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238401 Primary reporting owner

LANGE LOUIS G

Relationship: Director
Address: C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
Signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Award

Transaction value
Shares: +3,400
Change %: +49%
Price
Shares after: 10,360
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAMS transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +15,300
Change %
Price: $0.000000
Shares after: 15,300
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 15,300
Exercise price: $35.45
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Footnote F2

Each RSU was granted on January 7, 2026 for no consideration.

Footnote F3

The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings.

Footnote F4

All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.